keynote-224: pembrolizumab monotherapy for previously untreated hcc
Published 3 years ago • 62 plays • Length 3:22Download video MP4
Download video MP3
Similar videos
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
1:09
keynote-224: improving hcc outcomes with pembrolizumab
-
2:09
keynote-240: pembrolizumab in advanced hcc
-
3:02
keynote-224: second-line pembrolizumab’s value in hcc
-
1:11
dr. zhu discusses findings of the keynote-224 in hcc
-
4:32
first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
-
3:53
asco gi: updates in keynote-177, imbrave150 & claridhy
-
1:27
takeaways in hepatocellular carcinoma at asco gi 2023
-
2:08
dr. finn on studies of pembrolizumab in hepatocellular carcinoma
-
2:40
regorafenib plus pembrolizumab for first-line treatment of advanced hcc
-
4:07
80mg regorafenib plus pembrolizumab for 1l hcc
-
1:57
recent immunotherapy advances in hcc management
-
0:41
keystep-004: combination immunotherapy with lenvatinib for advanced hcc
-
1:36
cabozantinib in patients with hcc refractory to checkpoint inhibitors
-
3:06
jeff evans, asco 2018 – lenvatinib plus pembrolizumab in hepatocellular carcinoma
-
1:03:32
immunotherapy converts locally advanced hepatocellular carcinoma into resectable disease
-
1:07
optimizing hcc treatment with predicative biomarkers
-
34:21
the hcc treatment algorithm: new and emerging monotherapy, combination, and multimodal approaches
-
1:21
unmet needs in immunotherapy for hepatocellular carcinoma